Novavax：被低估的昔日新冠宠儿 (NASDAQ:NVAX)
· seekingalpha.com
Novavax 在后疫情时代被显著低估，当前企业价值约为 7.16 亿美元。阅读下文，了解我为何将 NVAX 股票评级为“买入”。
Novavax ( NVAX ) is a biotechnology company that was, during the COVID-19 time period, valued at over $19.5 billion; now it trades at just around $1.22 billion ...